Industrial studies for building craft students/ by 196667 Boucher, R. C.

Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy by Loke, J, Metzner, M, Boucher, R, Jackson, A, Hopkins, L, Pavlu, J, Tholouli, E, Drummond, M, Peniket, A, Bishop, R, Fox, S, Vyas, P, Craddock, C

Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study) by Sternberg, A, Boucher, R, Coulthard, HC, Raghavan, M, Culligan, D, Jackson, A, Cargo, C, Dennis, M, Metzner, M, O'Sullivan, J, Moore, R, Bowen, D, Vyas, P

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib by O'Sullivan, JM, Hamblin, A, Yap, C, Fox, S, Boucher, R, Panchal A, Alimam, S, Dreau, H, Howard, K, Ware, P, Cross, NCP, McMullin, MF, Harrison, CN, Mead, AJ

Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial by Harrison, CN, Nangalia, J, Boucher, R, Jackson, A, Yap, C, O'Sullivan, J, Fox, S, Ailts, I, Dueck, AC, Geyer, HL, Mesa, RA, Dunn, WG, Nadezhdin, E, Curto-Garcia, N, Green, A, Wilkins, B, Coppell, J, Laurie, J, Garg, M, Ewing, J, Knapper, S, Crowe, J, Chen, F, Koutsavlis, I, Godfrey, A, Arami, S, Drummond, M, Byrne, J, Clark, F, Mead-Harvey, C, Baxter, EJ, McMullin, MF, Mead, AJ